Integra LifeSciences reviews

Severe lack of foresight and rationale across the board by upper management and executives. Wound care will always be the company's focus, which is fine. But other divisions offer no long-term security as the company often takes a "throw it against the wall, see what sticks, and market the hell out of it" approach without a real plan and no realistic support. Overzealous compliance department and initiatives. Serious manufacturing problems in all divisions, constant state of backorder. Again, if you're not in wound care, do not feel good about your long-term outlook.

The current state of QA leadership within the company raises significant concerns. Despite their role, QA leadership appears to lack a proactive approach in supporting their subordinates, often advising to escalate issues without taking tangible steps towards resolution. Additionally, there is a notable lack of familiarity with established procedures, further hindering effective leadership. One critical issue is the refusal of QA leadership to access the NC and CAPA system. Moreover, during CAPA meetings, valuable time is consistently wasted on reiterating the details of the CAPA from the beginning, diverting focus from the primary purpose of the meeting. Another troubling aspect is QA leadership’s reluctance to assume the responsibility of signing off as the site quality lead. This reluctance places unqualified and untrained individuals in the position, potentially compromising the overall quality management at the site. Addressing these issues is paramount for the smooth functioning of the quality assurance department and the company as a whole. I recommend a thorough examination of these concerns and the implementation of corrective measures to ensure effective and knowledgeable leadership within the QA team.